Trial Comparing Relapse Rates Between Standard Ureteroscopic Removal Of Ureteral Stone And Standard Removal With Additional Ureterorenic Clearing Of Non-Symptomatic Stones In The Kidney

NCT ID: NCT02210650

Last Updated: 2022-05-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-30

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with a ureteral or kidney stone that causes symptoms, like pain, frequently have small kidney stones that don't cause symptoms. If these small kidney stones are determined to be asymptomatic (not causing any problems or pain), then most urologists will simply remove the symptomatic ureteral stone and leave the additional stones in the kidneys. However, symptomatic kidney stones started as small stones that didn't cause symptoms. This means that the small stones remaining in the patient's kidney may cause problems later. The purpose of our research is to test if removing small stones from the kidney prevents future stone episodes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ureteral Stones, Kidney Stones

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Symptomatic stone removal

Group 1 will receive the standard treatment of having only the symptomatic stone removed

Group Type OTHER

Symptomatic stone removal

Intervention Type PROCEDURE

Symptomatic stone removal by the surgical procedures called Ureteroscopy or Percutaneous Nephrolithotomy

Asymptomatic kidney stones and symptomatic stone removed

Group 2 will include the step of having the asymptomatic kidney stones removed in addition to the symptomatic stone

Group Type OTHER

Asymptomatic kidney stones and ureteral stone removed

Intervention Type PROCEDURE

Asymptomatic kidney stones and symptomatic stone removal by the surgical procedure called Ureteroscopy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Symptomatic stone removal

Symptomatic stone removal by the surgical procedures called Ureteroscopy or Percutaneous Nephrolithotomy

Intervention Type PROCEDURE

Asymptomatic kidney stones and ureteral stone removed

Asymptomatic kidney stones and symptomatic stone removal by the surgical procedure called Ureteroscopy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Scheduled to undergo surgery (URS or PCNL) for a primary stone.
* Computed tomography (CT) exam within the 90-day pre-operative period
* Small (≤ 6mm) asymptomatic stones in visible on KUB or CT (i.e., calcium stones) in the contralateral kidney for a primary renal stone or ipsilateral kidney for primary ureteral stone.
* Recurrent (having had previous stones) or multiple (simultaneous bilateral stones) stones
* Able to give informed consent
* Age 21 years or older

Exclusion Criteria

* Inability to give informed consent
* Age less than 21 years
* Stones not visible on KUB or CT
* Patients with systemic disease or renal anatomical disorders (RTA, primary hyperparathyroidism, sarcoidosis, enteric hyperoxaluria, medullary sponge kidney)
* Any condition (eg, psychiatric illness) or situation that, in the investigator's opinion, could put the
* subject at significant risk, confound the study results, or interfere significantly with the subject's
* participation in the study.
* Unwilling to participate.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Washington

OTHER

Sponsor Role collaborator

VA Puget Sound Health Care System

FED

Sponsor Role collaborator

Indiana Kidney Stone Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

James E Lingeman, MD

Role: PRINCIPAL_INVESTIGATOR

Indiana University Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Indiana University Health

Indianapolis, Indiana, United States

Site Status

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

University of Washington Medical Center Department of Urology

Seattle, Washington, United States

Site Status

Veterans Administration Puget Sound Heath Care System

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Sorensen MD, Harper JD, Borofsky MS, Hameed TA, Smoot KJ, Burke BH, Levchak BJ, Williams JC Jr, Bailey MR, Liu Z, Lingeman JE. Removal of Small, Asymptomatic Kidney Stones and Incidence of Relapse. N Engl J Med. 2022 Aug 11;387(6):506-513. doi: 10.1056/NEJMoa2204253.

Reference Type DERIVED
PMID: 35947709 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P01DK043881

Identifier Type: NIH

Identifier Source: secondary_id

View Link

P01 DK 043881 Project 3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Follow-Up of Ureteral Stones ≤4 mm
NCT07176026 ENROLLING_BY_INVITATION